Table 1 Baseline demographic and clinical characteristics of the patients a
Characteristics | Patients (N= 760) | Survivors (n= 387) | Nonsurvivors (n= 373) | P |
|---|---|---|---|---|
Mean age (yr) | 59.72 | 58.25 | 61.25 | 0.020 |
Male sex (%) | 498 (65.5) | 250 (64.6) | 248 (66.5) | 0.594 |
Premorbidity (%) | 496 (65.3) | 234 (60.5) | 262 (70.2) | 0.007 |
Cardiovascular disease | 171 | 78 | 93 | |
Liver disease | 94 | 37 | 57 | |
Pulmonary disease | 31 | 15 | 16 | |
Cancer | 77 | 34 | 43 | |
Renal disease | 63 | 41 | 22 | |
Hematological disease | 28 | 10 | 18 | |
Other | 32 | 19 | 13 | |
Recent surgery (%) | 272 (35.8) | 138 (35.7) | 134 (35.9) | >0.999 |
Sepsis (%) | 406 (53.4) | 188 (48.6) | 218 (58.4) | 0.010 |
Main source of infection (%) | ||||
Chest | 233 (57.3) | 97 (51.6) | 136 (62.4) | |
Abdomen | 118 (29.1) | 62 (33.0) | 56 (25.7) | |
Bloodstream, including line-related infection | 36 (8.9) | 20 (10.6) | 16 (7.3) | |
Other or unknown source | 19 (4.7) | 9 (4.8) | 10 (4.6) | |
APACHE II score (mean) | 21.04 | 19.42 | 22.72 | <0.001 |
Mean length of mechanical ventilation (days) | 8.01 | 8.30 | 7.70 | 0.290 |
Prescribed dose of CVVH (mean in first 72 hours, ml/kg/h) | 48.53 | 47.67 | 49.42 | 0.089 |
Delivered dose of CVVH (median in first 72 hours, ml/kg/h) | 41.00 | 40.32 | 41.71 | 0.542 |
Therapeutic time of CVVH (days) | 7.94 | 8.20 | 7.67 | 0.271 |
Phosphate supplementation (%) | 471 (62.0) | 248 (64.1) | 223 (59.8) | 0.232 |
Hypophosphatemia during CVVH (%) | 521 (68.6) | 260 (67.2) | 261 (70.0) | 0.435 |
Severe hypophosphatemia (%) | 109 (14.3) | 44 (11.4) | 65 (17.4) | 0.022 |